Equibles does not estimate personal net worth.
Get an email with a short summary when Phibro Animal Health Corp publishes a filing, an earnings call transcript or a press release.
Get PAHC alertsGlenn C. David is recorded as CFO at Phibro Animal Health Corp (PAHC). Phibro Animal Health Corp reported in an 8-K filed February 6, 2024 that Glenn C. David was appointed Chief Financial Officer, effective February 9, 2024. Glenn C. David has spoken on 6 earnings calls and 3 other investor events across 1 company, most recently for Phibro Animal Health Corp on September 15, 2026. Phibro Animal Health Corp is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Phibro Animal Health Corp includes Daniel (Dani) Bendheim (CEO), Gerald K. Carlson (CEO and Board Member), Carol A. Wrenn (Chairman) and 7 others.
“On February 6, 2024, Phibro Animal Health Corporation (“Phibro” or the “Company”) announced that Glenn C. David has joined Phibro and will assume the role of Chief Financial Officer effective February 9, 2024 (the “Start Date”), pursuant to the terms and conditions of that certain offer letter, entered into between Phibro and Mr. David dated October 12, 2023 (the “Offer Letter”).”
“Yeah, no, so we saw overall very good performance of the Zoetis portfolio in fiscal year 2026, and we actually expect, you know, sort of above our average growth rate for fiscal year 27, so we're seeing good continued momentum in the business.”
“Good day, and welcome to the Fibro Animal Health Corporation earnings call for our fiscal fourth quarter and full year ended June 30, 2026. My name is Glenn David, and I'm the Chief Financial Officer of Fibro Animal Health Corporation.”
“I'm just going to cover a few financial slides, starting with a little bit of a view of our historical revenue growth.”
“So the MFAs in total grew 13% for the quarter, and that was across both the legacy as well as the Zouetta's portfolio. So the legacy portfolio grew 5%. It's grown for the year as well.”
“I'm starting with a few brief performance on slide four. Consolidated net sales for this order ended March 31, 2026, worth $383.5 million, reflecting an increase of $35.7 million, or a 10% increase over the same quarter one year ago.”
Drug Manufacturers - Specialty & Generic · Healthcare
CFO
